Document is current
Any future updates will be listed below
-
Authors
Santofimia-Castaño, Patricia
Huang, Can
Liu, Xi
Xia, Yi
Audebert, Stephane https://orcid.org/0000-0002-9409-2588
Camoin, Luc https://orcid.org/0000-0002-1230-4787
Peng, Ling https://orcid.org/0000-0003-3990-5248
Lomberk, Gwen https://orcid.org/0000-0001-5463-789X
Urrutia, Raul https://orcid.org/0000-0002-1640-6780
Soubeyran, Philippe https://orcid.org/0000-0002-5876-3217
Neira, Jose Luis
Iovanna, Juan https://orcid.org/0000-0003-1822-2237
- License Information
-
More Information
Article History
Received: 19 November 2021
Accepted: 12 July 2022
First Online: 22 July 2022
Competing interests
: J.I. is co-founder of PanCa Therapeutics and PedictingMed. P.S.C., Y.X., L.P., J.L.N., and J.I. are inventors of the Patent “NUPR1 INHIBITION FOR TREATING CANCER”, Application number WO-2019229236-A1. The other authors declare no competing interests. This work was supported by La Ligue Contre le Cancer, INCa, Canceropole PACA, and INSERM. C.H. and X.L. are recipient of the predoctoral fellowship from China Scholarship Council (CSC).
